MolDX: Genetic Testing for Hereditary Thrombophilia

Genetic testing for hereditary (germline) thrombophilia is covered for patients with VTE when testing is expected to inform clinical management—specifically VTE associated with ASH-defined non-surgical major transient or hormonal risk factors or cerebral/splanchnic venous thrombosis where long-term anticoagulation decision-making is required. Covered tests include LDTs, FDA-cleared/approved tests and NGS when they include ASH-established minimal genetic content, are properly validated, do not include unvalidated/uncertain-content, do not conflict with repeat-testing policies L38351/L38353, and have completed a MolDX Technical Assessment.

"Genetic testing for hereditary thrombophilia is covered for patients with venous thromboembolism (VTE) when at least one of the following is present: VTE associated with non-surgical major transien..."

Sign up to see full coverage criteria, indications, and limitations.